Central Nervous System Biomarkers Global Market is Booming Across the Globe and Witness Huge Growth By Key Players To 2033 | The Business Research Company

The central nervous system biomarkers market size has grown rapidly in recent years. It will grow from $5.01 billion in 2023 to $5.55 billion in 2024 at a compound annual growth rate (CAGR) of 10.8%. The growth in the historic period can be attributed to rise in concerns regarding neurological disorders, high prevalence of central nervous system illnesses, growth in demand for enhanced diagnosis and treatment, improved healthcare infrastructure, rise in aging population.

The central nervous system biomarkers market size is expected to see strong growth in the next few years. It will grow to $8.02 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to increasing prevalence of neurological disorders, growing demand for personalized medicine, rising geriatric population, increasing focus on early diagnosis, growing demand for non-invasive diagnostic tools. Major trends in the forecast period include new technological advancements, strategic collaborations between biotechnology companies, pharmaceutical companies, and other stakeholders, growth in research on cerebrospinal fluid (csf) and blood-based biomarkers, utilization of ai and machine learning algorithms.

Market Overview -
Central nervous system (CNS) biomarkers refer to specific substances or measurable indicators in the CNS that provide information about normal functioning, disease processes, or responses to treatments within the CNS. These are used to diagnose or predict neurological disorders, monitor disease progression, and predict responses to drug therapy.

Download Free Sample of Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12632&type=smp

The Surge In Neurological Illnesses And The Central Nervous System Biomarker Market
The rise in neurological illnesses is expected to propel the growth of the central nervous system biomarker market going forward. Neurological illnesses, also known as neurological disorders, refer to a broad range of conditions that affect the brain, spinal cord, and nerves throughout the body. These disorders can arise from various causes, including genetic factors, infections, autoimmune responses, degenerative processes, tumors, vascular issues, and traumatic injuries. In neurological disorders, central nervous system (CNS) biomarkers aid clinical diagnosis, determine illness risk or prognosis, assess disease stage, and track treatment response. They play a significant role in understanding these diseases and their ability to be treated. For instance, in April 2023, according to the Centers for Disease Control and Prevention, a US-based government agency, Alzheimer's disease affected an estimated 6.7 million Americans aged 65 and older. This number is expected to nearly triple to 14 million by 2060. Moreover, the number of people living with the disease doubles every five years after age 65. Therefore, the rise in neurological illnesses drives the growth of the central nervous system biomarker market.

Competitive Landscape -
Major companies operating in the central nervous system biomarkers market report are F. Hoffmann-La Roche AG, Novartis AG, Siemens Healthineers, Thermo Fisher Scientific Inc, Abbott Laboratories, Merck KGaA, Eurofins Scientific, Charles River Laboratories International Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Axon Neuroscience SE, Alector Inc., Oryzon Genomics S.A., Abastar Mdx Inc., Banyan Biomarkers Inc., Avacta Group PLC, Geno Technology Inc., Anavex Life Sciences Corp., Alseres Pharmaceuticals Inc., Aposense Ltd., Applied Neurosolutions Inc., C2N Diagnostics, Alzheon Inc., DiaGenic ASA, Abiant Inc., Avid Radiopharmaceuticals Inc. , Acumen Pharmaceuticals Inc. , Cassava Sciences Inc., Denali Therapeutics.

Innovative Drug Approvals Shape The Central Nervous System Biomarker Landscape
Innovative drug approvals are a key trend gaining popularity in the central nervous system biomarker market. Major companies operating in the central nervous system biomarkers market are focused on developing innovative drugs and getting approval to strengthen their position in the market. For instance, in January 2022, Denovo Biopharma LLC, a US-based clinical-stage biopharmaceutical company, announced the US Food and Drug Administration's (FDA) approval and authorization of the company's investigational new drug (IND) application of DB104 (liafensine) for the treatment of treatment-resistant depression (TRD). It is the first biomarker-guided global CNS clinical trial for TRD. Additionally, it could help identify patients who are more likely to respond to liafensine, which could lead to more personalized treatment decisions. Liafensine is a novel compound that works by increasing levels of dopamine and norepinephrine in the brain.

Browse Full Report @
https://www.thebusinessresearchcompany.com/report/central-nervous-system-biomarkers-global-market-report

Key Segments -
The central nervous system biomarkers market covered in this report is segmented -
1) By Type: Safety Biomarker, Efficacy Biomarker, Validation Biomarker, Other Types
2) By Disease: Multiple Sclerosis, Alzheimer's Disease, Parkinson's Disease, Traumatic Brain Injury, Other Diseases
3) By Application: Drug Discovery And Development, Personalized Medicines, Disease Risk Assessment, Diagnostics, Other Applications
4) By End-Users: Diagnostic Labs, Clinics, Hospitals, Research Centers, Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.